{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:58:43Z","timestamp":1790794723347,"version":"4.1.0"},"reference-count":76,"publisher":"Begell House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>Natural killer (NK) cells play critical roles in innate immunity and in shaping adaptive immune responses. Recent studies reveal their dual role in autoimmunity, either with a protective role by eliminating autoreactive cells or as contributors to pathogenic inflammation. This review summarizes current understanding of NK cell biology in endocrine autoimmune diseases, focusing on what is known for type 1 diabetes and autoimmune adrenal failure-Addison's disease. We further discuss emerging therapeutic approaches focusing on cytokine-activated (supercharged) NK cells and CAR NK cells, and highlight knowledge gaps and future priorities.<\/p>","DOI":"10.1615\/critrevimmunol.2026062734","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:57:15Z","timestamp":1779998235000},"page":"75-86","source":"Crossref","is-referenced-by-count":0,"title":["NK Cells In Endocrine Autoimmune Disorders: Current Knowledge and Implications for Therapeutic Strategies"],"prefix":"10.1615","volume":"46","author":[{"given":"Dorsa","family":"Iraji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Sj\u00f8gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bergithe E.","family":"Oftedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Herberman RB, Nunn ME, Lavrin DH, Asofsky R. Effect of antibody to theta antigen on cell-mediated immunity induced in syngeneic mice by murine sarcoma virus. J Natl Cancer Inst. 1973;51(5):1509\u201312.","DOI":"10.1093\/jnci\/51.5.1509"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Kiessling R, Klein E, Wigzell H. 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5(2):112\u20137.","DOI":"10.1002\/eji.1830050208"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Scoville SD, Freud AG, Caligiuri MA. Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells. Front Immunol. 2017;8(360).","DOI":"10.3389\/fimmu.2017.00360"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633\u201340.","DOI":"10.1016\/S1471-4906(01)02060-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136(12):4480\u20136.","DOI":"10.4049\/jimmunol.136.12.4480"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, Merli P, Locatelli F, Mingari MC. Human natural killer cells: origin, receptors, function, and clinical applications. Int Arch Allergy Immunol. 2014;164(4):253\u201364.","DOI":"10.1159\/000365632"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Crinier A, Milpied P, Escaliere B, Piperoglou C, Galluso J, Balsamo A, Spinelli L, Cervera-Marzal I, Ebbo M, Girard-Madoux M, Jaeger S, Bollon E, Hamed S, Hardwigsen J, Ugolini S, Vely F, Narni-Mancinelli E, Vivier E. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. Immunity. 2018;49(5):971\u201386 e975.","DOI":"10.1016\/j.immuni.2018.09.009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293\u2013300.","DOI":"10.1038\/nature08933"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Herold KC, Delong T, Perdigoto AL, Biru N, Brusko TM, Walker LSK. The immunology of type 1 diabetes. Nat Rev Immunol. 2024;24(6):435\u201351.","DOI":"10.1038\/s41577-023-00985-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, Falorni A, Gan EH, Hulting AL, Kasperlik-Zaluska A, Kampe O, Lovas K, Meyer G, Pearce SH. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med. 2014;275(2):104\u201315.","DOI":"10.1111\/joim.12162"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Husebye ES, Pearce SH, Krone NP, Kampe O. Adrenal insufficiency. Lancet. 2021 Feb 13;397(10274):613-629.","DOI":"10.1016\/S0140-6736(21)00136-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Hellesen A, Aslaksen S, Breivik L, Royrvik EC, Bruserud O, Edvardsen K, Brokstad KA, Wolff ASB, Husebye ES, Bratland E. 21-hydroxylase-specific CD8+ T cells in autoimmune Addison's disease are restricted by HLA-A2 and HLA-C7 molecules. Front Immunol. 2021;12(742848).","DOI":"10.3389\/fimmu.2021.742848"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Boos MD, Ramirez K, Kee BL. Extrinsic and intrinsic regulation of early natural killer cell development. Immunol Res. 2008;40(3):193\u2013207.","DOI":"10.1007\/s12026-007-8006-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends Immunol. 2013;34(12):573\u201382.","DOI":"10.1016\/j.it.2013.07.005"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Jiang H, Jiang J. Balancing act: the complex role of NK cells in immune regulation. Front Immunol. 2023;14(1275028).","DOI":"10.3389\/fimmu.2023.1275028"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Bjorklund AT, Flodstrom-Tullberg M, Michaelsson J, Rottenberg ME, Guzman CA, Ljunggren HG, Malmberg KJ. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116(19):3853\u201364.","DOI":"10.1182\/blood-2010-04-281675"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167\u201376.","DOI":"10.1182\/blood-2009-08-238469"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010;116(19):3865\u201374.","DOI":"10.1182\/blood-2010-04-282301"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Fu B, Tian Z, Wei H. Subsets of human natural killer cells and their regulatory effects. Immunology. 2014;141(4):483\u20139.","DOI":"10.1111\/imm.12224"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Tian Z, Gershwin ME, Zhang C. Regulatory NK cells in autoimmune disease. J Autoimmun. 2012;39(3):206\u201315.","DOI":"10.1016\/j.jaut.2012.05.006"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: An important NK cell subset. Immunology. 2009;126(4):458\u201365.","DOI":"10.1111\/j.1365-2567.2008.03027.x"},{"key":"22","unstructured":"Bahadorian D, Mollazadeh S, Mirazi H, Faraj TA, Kheder RK, Esmaeili SA. Regulatory NK cells in autoimmune disease. Iran J Basic Med Sci. 2023;26(6):609\u201316."},{"key":"23","doi-asserted-by":"crossref","unstructured":"Martinez-Espinosa I, Serrato JA, Ortiz-Quintero B. Role of IL-10-producing natural killer cells in the regulatory mechanisms of inflammation during systemic infection. Biomolecules. 2021;12(1):","DOI":"10.3390\/biom12010004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Pesce S, Moretta L, Moretta A, Marcenaro E. Human NK cell subsets redistribution in pathological conditions: A role for CCR7 receptor. Front Immunol. 2016;7(414).","DOI":"10.3389\/fimmu.2016.00414"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Niehrs A, Hertwig L, Buggert M, Nordstr\u00f6m I, Statzu M, Pampena MB, Samer S, Knox JJ, Strunz B, Sun D, Nguyen S. Transient tissue residency and lymphatic egress define human CD56bright NK cell homeostasis. Nature Immunol. 2025;26(11):2004\u201315.","DOI":"10.1038\/s41590-025-02290-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, Kubota M, Matsumoto R, Thapa P, Szabo PA, Li Poon MM, Li J, Arakawa-Hoyt J, Shen Y, Fong L, Lanier LL, Farber DL. Tissue determinants of human NK cell development, function, and residence. Cell. 2020;20(4):749\u2013763 e713.","DOI":"10.1016\/j.cell.2020.01.022"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity. 2005;22(3):295\u2013304.","DOI":"10.1016\/j.immuni.2005.01.013"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Vacca P, Vitale C, Montaldo E, Conte R, Cantoni C, Fulcheri E, Darretta V, Moretta L, Mingari MC. CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci U S A. 2011;108(6):2402\u20137.","DOI":"10.1073\/pnas.1016257108"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Dowell AC, Oldham KA, Bhatt RI, Lee SP, Searle PF. Long-term proliferation of functional human NK cells, with conversion of CD56dim NK cells to a CD56bright phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12. Cancer Immunol Immunother. 2012;61(5):615\u201328.","DOI":"10.1007\/s00262-011-1122-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Rebuffet L, Melsen JE, Escaliere B, Basurto-Lozada D, Bhandoola A, Bjorkstrom NK, Bryceson YT, Castriconi R, Cichocki F, Colonna M, Davis DM, Diefenbach A, Ding Y, Haniffa M, Horowitz A, Lanier LL, Malmberg KJ, Miller JS, Moretta L, Narni-Mancinelli E, O'Neill LAJ, Romagnani C, Ryan DG, Sivori S, Sun D, Vagne C, Vivier E. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat Immunol. 2024;25(8):1474\u201388.","DOI":"10.1038\/s41590-024-01883-0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Trapani JA, Sutton VR. Granzyme B: Pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol. 2003;15(5):533\u201343.","DOI":"10.1016\/S0952-7915(03)00107-9"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Zhao T, Zhang H, Guo Y, Zhang Q, Hua G, Lu H, Hou Q, Liu H, Fan Z. Granzyme K cleaves the nucleosome assembly protein SET to induce single-stranded DNA nicks of target cells. Cell Death Differ. 2007;14(3):489\u201399.","DOI":"10.1038\/sj.cdd.4402040"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Fellows E, Gil-Parrado S, Jenne DE, Kurschus FC. Natural killer cell-derived human granzyme H induces an alternative, caspase-independent cell-death program. Blood. 2007;110(2):544\u201352.","DOI":"10.1182\/blood-2006-10-051649"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Holmes TD, Pandey RV, Helm EY. The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. Sci Immunol. 2021;6(57).","DOI":"10.1126\/sciimmunol.abc9801"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Ruckert T, Lareau CA, Mashreghi MF, Ludwig LS, Romagnani C. Clonal expansion and epigenetic inheritance of long-lasting NK cell memory. Nat Immunol. 2022;23(11):1551\u201363.","DOI":"10.1038\/s41590-022-01327-7"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Liu R, Van Kaer L, La Cava A, Price M, Campagnolo DI, Collins M, Young DA, Vollmer TL, Shi FD. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol. 2006;176(9):5247\u201354.","DOI":"10.4049\/jimmunol.176.9.5247"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Wang X, Zhang Y, Jin Y, Dai L, Yue Y, Hu J, Liu X, Pang K, Ye S, Chen Y, Ye W, Shi X, Ma X, Guo L, Liu Y, Ta N, Zhu X, Lin L, Wang J, Yan R, Wang P, Song X, Zhou Y, Zhou L, Wang Q, Guan T, Li T, Zhou L, Pan W, He Y, Wu X, Xu Y, Yang L, Xu H. An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell. 2025;188(16):4225\u201338 e4212.","DOI":"10.1016\/j.cell.2025.05.038"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221\u20139.","DOI":"10.1016\/S0140-6736(01)05415-0"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Chiou J, Geusz RJ, Okino ML, Han JY, Miller M, Melton R, Beebe E, Benaglio P, Huang S, Korgaonkar K, Heller S, Kleger A, Preissl S, Gorkin DU, Sander M, Gaulton KJ. Interpreting type 1 diabetes risk with genetics and single-cell epigenomics. Nature. 2021;594(7863):398\u2013402.","DOI":"10.1038\/s41586-021-03552-w"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Husebye ES, Anderson MS. Autoimmune polyendocrine syndromes: Clues to type 1 diabetes pathogenesis. Immunity. 2010;32(4):479\u201387.","DOI":"10.1016\/j.immuni.2010.03.016"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Gardner G, Fraker CA. Natural killer cells as key mediators in type I diabetes immunopathology. Front Immunol. 2021;12:722979.","DOI":"10.3389\/fimmu.2021.722979"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci U S A. 2004;101(21):8102\u20137.","DOI":"10.1073\/pnas.0402065101"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, Achdout H, Ghadially H, Dor Y, Nir T, Doviner V, Hershkovitz O, Mendelson MM, Naparstek Y, Mandelboim O. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol. 2010;11(2):121\u20138.","DOI":"10.1038\/ni.1834"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Angstetra E, Graham KL, Zhao Y, Irvin AE, Elkerbout L, Santamaria P, Slattery RM, Kay TW, Thomas HE. An indirect role for NK cells in a CD4(+) T-cell-dependent mouse model of type I diabetes. Immunol Cell Biol. 2012;90(2):243\u20137.","DOI":"10.1038\/icb.2011.16"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Berhani O, Glasner A, Kahlon S, Duev-Cohen A, Yamin R, Horwitz E, Enk J, Moshel O, Varvak A, Porgador A, Jonjic S, Mandelboim O. Human anti-NKp46 antibody for studies of NKp46-dependent NK cell function and its applications for type 1 diabetes and cancer research. Eur J Immunol. 2019;49(2):228\u201341.","DOI":"10.1002\/eji.201847611"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Lee IF, Qin H, Priatel JJ, Tan R. Critical role for IFNgamma in natural killer cell-mediated protection from diabetes. Eur J Immunol. 2008;38(1):82\u20139.","DOI":"10.1002\/eji.200737189"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Lee IF, Qin H, Trudeau J, Dutz J, Tan R. Regulation of autoimmune diabetes by complete Freund\u2019s adjuvant is mediated by NK cells. J Immunol. 2004;172(2):937\u201342.","DOI":"10.4049\/jimmunol.172.2.937"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Gomez-Munoz L, Perna-Barrull D, Villalba A, Rodriguez-Fernandez S, Ampudia RM, Teniente-Serra A, Vazquez F, Murillo M, Perez J, Corripio R, Bel J. NK cell subsets changes in partial remission and early stages of pediatric type 1 diabetes. Front Immunol. 2021;11:611522.","DOI":"10.3389\/fimmu.2020.611522"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Qin H, Lee IF, Panagiotopoulos C, Wang X, Chu AD, Utz PJ, Priatel JJ, Tan R. Natural killer cells from children with type 1 diabetes have defects in NKG2D-dependent function and signaling. Diabetes. 2011;60(3):857\u201366.","DOI":"10.2337\/db09-1706"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Gur C, Enk J, Kassem SA, Suissa Y, Magenheim J, Stolovich-Rain M, Nir T, Achdout H, Glaser B, Shapiro J, Naparstek Y, Porgador A, Dor Y, Mandelboim O. Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol. 2011;187(6):3096\u2013103.","DOI":"10.4049\/jimmunol.1101269"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen Gross T, Katz G, Bar-Ilan A, Bloushtain N, Lev M, Joseph A, Kedar E, Porgador A, Mandelboim O. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood. 2004 15;103(2):664\u201372.","DOI":"10.1182\/blood-2003-05-1716"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Radenkovic M, Uvebrant K, Skog O, Sarmiento L, Avartsson J, Storm P, Vickman P, Bertilsson PA, Fex M, Korgsgren O, Cilio CM. Characterization of resident lymphocytes in human pancreatic islets. Clin Exp Immunol. 2017;187(3):418-427.","DOI":"10.1111\/cei.12892"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Bratland E, Husebye ES. Cellular immunity and immunopathology in autoimmune Addison\u2019s disease. Mol Cell Endocrinol. 2011;336(1-2):180\u201390.","DOI":"10.1016\/j.mce.2010.12.015"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Bancos I, Hazeldine J, Chortis V, Hampson P, Taylor AE, Lord JM, Arlt W. Primary adrenal insufficiency is associated with impaired natural killer cell function: A potential link to increased mortality. Eur J Endocrinol. 2017;176(4):471\u201380.","DOI":"10.1530\/EJE-16-0969"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Nowotny HF, Marchant Seiter T, Ju J, Gottschlich A, Schneider H, Zopp S, Vogel F, Tschaidse L, Auer MK, Lottspeich C, Kobold S, Rothenfusser S, Beuschlein F, Reincke M, Braun L, Reisch N. Major immunophenotypic abnormalities in patients with primary adrenal insufficiency of different etiology. Front Immunol. 2023;14:1275828.","DOI":"10.3389\/fimmu.2023.1275828"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002;23(3):327\u201364.","DOI":"10.1210\/edrv.23.3.0466"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Husebye ES, Anderson MS, Kampe O. Autoimmune polyendocrine syndromes. N Engl J Med. 2018;378(12):1132\u201341.","DOI":"10.1056\/NEJMra1713301"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Hellesen A, Bratland E. The potential role for infections in the pathogenesis of autoimmune Addison\u2019s disease. Clin Exp Immunol. 2019;195(1):52\u201363.","DOI":"10.1111\/cei.13207"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Gao J, Li M, Sun M, Yu Y, Kong R, Xu X, Liu S, Chen Q, Li X, Wu Y, Xu E, Yang J, Zhao D. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: A case series in China. Lancet. 2025;12","DOI":"10.1016\/j.ard.2025.05.396"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Jorgensen LV, Christensen EB, Barnkob MB, Barington T. The clinical landscape of CAR NK cells. Exp Hematol Oncol. 2025;14(1):46.","DOI":"10.1186\/s40164-025-00633-8"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Muller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Volkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schafer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Kronke G, Mackensen A, Schett G. CD19 CAR T-cell therapy in autoimmune disease: A case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700.","DOI":"10.1056\/NEJMoa2308917"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Yu J, Yang Y, Gu Z, Shi M, La Cava A, Liu A. CAR immunotherapy in autoimmune diseases: Promises and challenges. Front Immunol. 2024;15(14):61102.","DOI":"10.3389\/fimmu.2024.1461102"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Daher M, Rezvani K. iPSC-derived CAR-NK cells: Off-the-shelf cellular therapy for systemic sclerosis. Cell. 2025;188(16):4173\u20134.","DOI":"10.1016\/j.cell.2025.07.007"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Liu R, Luo Q, Luo W, Wan L, Zhu Q, Yin X, Lu X, Song Z, Wei L, Xiang Z, Zou Y. A Soluble NK-CAR mediates the specific cytotoxicity of NK cells toward the target CD20(+) lymphoma cells. Aging Dis. 2022;13(5):1576\u201388.","DOI":"10.14336\/AD.2022.0415"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Kaur K, Chen PC, Jewett A. Supercharged NK cells: A unique population of NK cells capable of differentiating stem cells and lysis of MHC class I high differentiated tumors. Cell Death Dis. 2025;16(1):665.","DOI":"10.1038\/s41419-025-07986-2"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Zhang J, Ma L, Deng H, Yi W, Tohtihan A, Tang X, Wu X, Feng X. Multi-omics integration identifies NK cell-mediated cytotoxicity as a therapeutic target in systemic lupus erythematosus. Front Immunol. 2025;16:1580540.","DOI":"10.3389\/fimmu.2025.1580540"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Li YR, Zhu Y, Fang Y, Lyu Z, Yang L. Emerging trends in clinical allogeneic CAR cell therapy. Med. 2025;6(8):100677.","DOI":"10.1016\/j.medj.2025.100677"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Kumar A, Fischer C, Cichocki F, Miller JS. Multiplexed iPSC platform for advanced NK cell immunotherapies. Cell Rep Med. 2025;6(11):102282.","DOI":"10.1016\/j.xcrm.2025.102282"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Guo JH, Afzal A, Ahmad S, Saeed G, Rehman A, Saddozai UaK, Liu L, Guo SH, Ji XY, Khawar MB. Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells. Front Immunol. 2025;16:1550652.","DOI":"10.3389\/fimmu.2025.1550652"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Lieberman J, Fan Z. Nuclear war: The granzyme A-bomb. Curr Opin Immunol. 2003;15(5):553\u20139.","DOI":"10.1016\/S0952-7915(03)00108-0"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Kucuksezer UC, Aktas Cetin E, Esen F, Tahrali I, Akdeniz N, Gelmez MY, Deniz G. The role of natural killer cells in autoimmune diseases. Front Immunol. 2021;25(12):622306.","DOI":"10.3389\/fimmu.2021.622306"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Liu M, Liang S, Zhang C. NK cells in autoimmune diseases: Protective or pathogenic? Front Immunol. 2021;(12):624687.","DOI":"10.3389\/fimmu.2021.624687"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Yang Y, Day J, Souza-Fonseca Guimaraes F, Wicks IP, Louis C. Natural killer cells in inflammatory autoimmune diseases. Clin Transl Immunol. 2021;10(2):e1250.","DOI":"10.1002\/cti2.1250"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cells: Functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther. 2024;9(1):302.","DOI":"10.1038\/s41392-024-02005-w"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. Arthritis Res Ther. 2013;15(4):216.","DOI":"10.1186\/ar4232"},{"key":"76","doi-asserted-by":"crossref","unstructured":"Gao J, Li M, Sun M, Yu Y, Kong R, Xu X, Liu S, Chen Q, Li X, Wu Y, Xu E, Yang J, Zhao D. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: A case series in China. Lancet. 2026;406(10522):2968\u201379.","DOI":"10.1016\/S0140-6736(25)01671-X"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/2f94912872170f8d\/CRI-62734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:33:03Z","timestamp":1790793183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,3cd8f7141fb7b275,2f94912872170f8d.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2026062734","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}